Primary peritoneal cancer (PPC) is a rare malignancy closely related to epithelial ovarian cancer, originating from the peritoneum lining the abdominal cavity. Cancer research is pivotal in improving PPC outcomes, focusing on early detection, targeted therapies, and understanding genetic predispositions. Advances in genomic profiling have identified key mutations, facilitating personalized treatment approaches. Research into biomarkers is underway to develop non-invasive diagnostic tools, enhancing early detection rates. Additionally, innovative treatments like PARP inhibitors and immunotherapy are being explored to improve survival rates. Collaborative clinical trials continue to play a critical role, aiming to refine existing therapies and discover new ones, offering hope for PPC patients through cutting-edge scientific advancements.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China